UC-MSC-Based Stem Cell Therapy for Torn Meniscus

One of the most frequent knee injuries, a torn meniscus, frequently affects athletes and physically active people. A promising, minimally invasive method for healing and regenerating the injured meniscal tissue is stem cell therapy, especially when combined with umbilical cord-derived mesenchymal stem cells (UC-MSCs). This could eliminate the need for surgery.

How UC-MSC Therapy Works for Meniscus Tears

1. Regeneration of Cartilage and Fibrocartilage:
   • UC-MSCs differentiate into chondrocytes and fibrocartilage cells, aiding in the reconstruction of meniscal tissue.
2. Anti-inflammatory Effects:
   • UC-MSCs reduce inflammation in the knee joint, which accelerates healing and alleviates pain.
3. Secretion of Growth Factors:
   • Release of cytokines and paracrine signals promotes tissue repair, angiogenesis, and reduction of scar formation.
4. Immunomodulation:
   • UC-MSCs help regulate the immune response, preventing excessive inflammation and tissue degradation.

Procedure Overview

1. Initial Assessment:
   • MRI and physical examinations confirm the extent and location of the torn meniscus.
   • Patients with degenerative or traumatic tears are evaluated for eligibility.
2. Stem Cell Sourcing:
   • UC-MSCs are sourced from Wharton’s jelly of the umbilical cord, ensuring high proliferation capacity and low immunogenicity.
3. Injection Procedure:
   • UC-MSCs are injected into the affected torn meniscus using ultrasound guidance to ensure precise delivery to the damaged meniscus.
4. Rehabilitation:
   • Patients undergo physical therapy post-procedure to enhance mobility and support the healing process.

Benefits of UC-MSC Therapy for Torn Meniscus

1. Non-surgical Option:
   • Reduces the need for invasive surgeries like partial or total meniscectomy.
2. Accelerated Healing:
   • Faster recovery due to the regenerative properties of UC-MSCs.
3. Pain Relief:
   • Reduction in joint inflammation and associated pain of torn meniscus.
4. Restoration of Torn Meniscus:
   • Enhanced joint stability and improved mobility.
5. Lower Risk of Osteoarthritis:
   • Preserving meniscal integrity reduces the likelihood of developing post-injury osteoarthritis.

Clinical Evidence

Studies have shown that UC-MSCs:

• Improve tissue integration and meniscal regeneration in patients with partial or full- torn meniscus.
• Enhance functional outcomes, such as improved range of motion and reduced knee pain scores.
• Provide better results in patients treated within 6-12 months of the injury.

Typical Dosage for UC-MSCs in Torn Meniscus:

1. Cell Count Per Injection:
   • 1 to 10 million cells per kilogram of body weight is a commonly used range in clinical practice.
   • For localized applications like a torn meniscus, the dose is typically 10–50 million cells per injection.
2. Injection Frequency:
   • Often a single injection is sufficient for mild cases.
   • For more severe injuries or chronic conditions, multiple injections may be recommended, spaced weeks to months apart.
3. Volume of Injection:
   • The injection volume is usually between 1–5 mL, containing the concentrated stem cells in saline or another carrier solution.
   • The injection is administered directly into the joint space under imaging guidance (ultrasound or fluoroscopy) for precision.

Factors Affecting Dosage:

1. Injury Severity:
   • A more extensive torn meniscus may require a higher stem cells dosage to maximize therapeutic effects.
2. Patient’s Body Weight:
   • Dosing is sometimes adjusted based on the patient’s size to ensure optimal results.
3. Age and Health:
   • Younger, healthier patients may require lower stem cells doses due to better natural regenerative capacity.
4. Combination Therapies:
   • When combined with Platelet-Rich Plasma (PRP) or other regenerative treatments, lower stem cell doses may be sufficient.

Considerations and Challenges

1. Patient Selection:
   • UC-MSC therapy is more effective for partial tears and early-stage injuries compared to chronic or completely torn meniscus.
2. Cost:
   • Stem cell treatments can be costly and are not always covered by insurance.
3. Regulatory Approval:
   • Therapy must comply with local regulations, including safety and quality standards.
4. Adjunct Rehabilitation:
   • Success depends on adherence to a tailored rehabilitation program post-injection.

Prospects for the Future

Torn Meniscus may be further improved by research into bioprinted scaffolds containing UC-MSCs and combination therapies (such as PRP or hyaluronic acid). With improvements, UC-MSC therapy may replace torn meniscus repair as the go-to method, offering both functional recovery and long-term comfort.